Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(1):6–13. doi: 10.1038/bjc.1998.434

A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

T Gulliford 1, J English 1, K W Colston 1, P Menday 1, S Moller 1, R C Coombes 1
PMCID: PMC2062933  PMID: 9662243

Abstract

Preclinical studies have shown that the vitamin D analogue EB 1089 has significantly less calcaemic activity than its parent compound 1,25-dihydroxyvitamin D (1,25(OH)2D3) and significant anti-tumour activity. This phase I trial was designed to evaluate the calcaemic effect of the drug in patients with advanced cancer. EB 1089 was given to 36 patients with advanced breast and colorectal cancer in doses of between 0.15 and 17.0 microg m(-2) day(-1). Serial serum and urine calcium, urine creatinine and serum parathyroid hormone (PTH) were monitored. Hypercalcaemia was seen in all patients receiving 17.0 microg m(-2) day(-1). Hypercalcaemia attributable to EB 1089 was reversible by discontinuing or reducing EB 1089 therapy. During the first 5 days of treatment, urine calcium (P = 0.0001) and serum-corrected calcium (P = 0.027) were related to EB 1089 dose, whereas serum parathyroid hormone (P = 0.0001) showed an inverse relationship. Twenty-one patients received compassionate treatment for between 10 and 234 days. No complete or partial responses were seen. Six patients on treatment for more than 90 days showed stabilization of disease. EB 1089 was well tolerated and adverse events considered to be caused by EB 1089 were limited to dose-dependent effects on calcium metabolism. The dose estimated to be tolerable for most patients from this study is around 7 microg m(-2) day(1). These data support previous work that has demonstrated EB 1089 to be significantly less calcaemic than 1,25-dihydroxyvitamin D3.

Full text

PDF
6

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., Yoshiki S., Suda T. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990–4994. doi: 10.1073/pnas.78.8.4990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akhter J., Chen X., Bowrey P., Bolton E. J., Morris D. L. Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis Colon Rectum. 1997 Mar;40(3):317–321. doi: 10.1007/BF02050422. [DOI] [PubMed] [Google Scholar]
  3. Bagot M., Grossman R., Pamphile R., Binderup L., Charue D., Revuz J., Dubertret L. Additive effects of calcipotriol and cyclosporine A: from in vitro experiments to in vivo applications in the treatment of severe psoriasis. C R Acad Sci III. 1994 Mar;317(3):282–286. [PubMed] [Google Scholar]
  4. Bar-Shavit Z., Teitelbaum S. L., Reitsma P., Hall A., Pegg L. E., Trial J., Kahn A. J. Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A. 1983 Oct;80(19):5907–5911. doi: 10.1073/pnas.80.19.5907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Berger U., Wilson P., McClelland R. A., Colston K., Haussler M. R., Pike J. W., Coombes R. C. Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res. 1987 Dec 15;47(24 Pt 1):6793–6799. [PubMed] [Google Scholar]
  6. Bertoli M., Luisetto G., Ruffatti A., Urso M., Romagnoli G. Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol. 1990 Feb;33(2):98–102. [PubMed] [Google Scholar]
  7. Binderup L., Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988 Mar 1;37(5):889–895. doi: 10.1016/0006-2952(88)90177-3. [DOI] [PubMed] [Google Scholar]
  8. Bower M., Colston K. W., Stein R. C., Hedley A., Gazet J. C., Ford H. T., Combes R. C. Topical calcipotriol treatment in advanced breast cancer. Lancet. 1991 Mar 23;337(8743):701–702. doi: 10.1016/0140-6736(91)90280-3. [DOI] [PubMed] [Google Scholar]
  9. Brehier A., Thomasset M. Human colon cell line HT-29: characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone. J Steroid Biochem. 1988 Feb;29(2):265–270. doi: 10.1016/0022-4731(88)90275-0. [DOI] [PubMed] [Google Scholar]
  10. Carlberg C. Mechanisms of nuclear signalling by vitamin D3. Interplay with retinoid and thyroid hormone signalling. Eur J Biochem. 1995 Aug 1;231(3):517–527. [PubMed] [Google Scholar]
  11. Colston K. W., Mackay A. G., James S. Y., Binderup L., Chander S., Coombes R. C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol. 1992 Dec 15;44(12):2273–2280. doi: 10.1016/0006-2952(92)90669-a. [DOI] [PubMed] [Google Scholar]
  12. Colston K., Colston M. J., Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981 Mar;108(3):1083–1086. doi: 10.1210/endo-108-3-1083. [DOI] [PubMed] [Google Scholar]
  13. Eisman J. A., Barkla D. H., Tutton P. J. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987 Jan 1;47(1):21–25. [PubMed] [Google Scholar]
  14. Elstner E., Lee Y. Y., Hashiya M., Pakkala S., Binderup L., Norman A. W., Okamura W. H., Koeffler H. P. 1 alpha,25-Dihydroxy-20-epi-vitamin D3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood. 1994 Sep 15;84(6):1960–1967. [PubMed] [Google Scholar]
  15. Elstner E., Linker-Israeli M., Umiel T., Le J., Grillier I., Said J., Shintaku I. P., Krajewski S., Reed J. C., Binderup L. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 1996 Aug 1;56(15):3570–3576. [PubMed] [Google Scholar]
  16. Frampton R. J., Omond S. A., Eisman J. A. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res. 1983 Sep;43(9):4443–4447. [PubMed] [Google Scholar]
  17. Gordeladze J. O., Halse J., Djøoseland O., Haugen H. N. A simple procedure for the determination of hydroxyproline in urine and bone. Biochem Med. 1978 Aug;20(1):23–30. doi: 10.1016/0006-2944(78)90046-7. [DOI] [PubMed] [Google Scholar]
  18. Hannah S. S., Norman A. W. 1 alpha,25(OH)2 vitamin D3-regulated expression of the eukaryotic genome. Nutr Rev. 1994 Nov;52(11):376–382. doi: 10.1111/j.1753-4887.1994.tb01368.x. [DOI] [PubMed] [Google Scholar]
  19. Hansen C. M., Frandsen T. L., Brünner N., Binderup L. 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis. 1994 May;12(3):195–202. doi: 10.1007/BF01753887. [DOI] [PubMed] [Google Scholar]
  20. Haq M., Kremer R., Goltzman D., Rabbani S. A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest. 1993 Jun;91(6):2416–2422. doi: 10.1172/JCI116475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hayward J. L., Rubens R. D. UICC Multidisciplinary Project on breast cancer. Management of early and advanced breast cancer. Int J Cancer. 1987 Jan 15;39(1):1–5. doi: 10.1002/ijc.2910390102. [DOI] [PubMed] [Google Scholar]
  22. Hosomi J., Hosoi J., Abe E., Suda T., Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology. 1983 Dec;113(6):1950–1957. doi: 10.1210/endo-113-6-1950. [DOI] [PubMed] [Google Scholar]
  23. James S. Y., Mackay A. G., Binderup L., Colston K. W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol. 1994 Jun;141(3):555–563. doi: 10.1677/joe.0.1410555. [DOI] [PubMed] [Google Scholar]
  24. James S. Y., Mackay A. G., Colston K. W. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol. 1995 Jun;14(3):391–394. doi: 10.1677/jme.0.0140391. [DOI] [PubMed] [Google Scholar]
  25. Kragballe K., Gjertsen B. T., De Hoop D., Karlsmark T., van de Kerkhof P. C., Larkö O., Nieboer C., Roed-Petersen J., Strand A., Tikjøb G. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet. 1991 Jan 26;337(8735):193–196. doi: 10.1016/0140-6736(91)92157-w. [DOI] [PubMed] [Google Scholar]
  26. Kragballe K. Vitamin D analogues in the treatment of psoriasis. J Cell Biochem. 1992 May;49(1):46–52. doi: 10.1002/jcb.240490109. [DOI] [PubMed] [Google Scholar]
  27. Majewski S., Szmurlo A., Marczak M., Jablonska S., Bollag W. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett. 1993 Nov 30;75(1):35–39. doi: 10.1016/0304-3835(93)90204-m. [DOI] [PubMed] [Google Scholar]
  28. Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995 Dec 15;83(6):835–839. doi: 10.1016/0092-8674(95)90199-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Norman A. W., Zhou J. Y., Henry H. L., Uskokovic M. R., Koeffler H. P. Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res. 1990 Nov 1;50(21):6857–6864. [PubMed] [Google Scholar]
  30. O'Quigley J., Pepe M., Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990 Mar;46(1):33–48. [PubMed] [Google Scholar]
  31. Skowronski R. J., Peehl D. M., Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 1993 May;132(5):1952–1960. doi: 10.1210/endo.132.5.7682937. [DOI] [PubMed] [Google Scholar]
  32. Thomas M. G., Tebbutt S., Williamson R. C. Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut. 1992 Dec;33(12):1660–1663. doi: 10.1136/gut.33.12.1660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tvedegaard E., Madsen S. Alphacalcidol and renal function in normal subjects. Miner Electrolyte Metab. 1988;14(2-3):158–162. [PubMed] [Google Scholar]
  34. Vieth R. The mechanisms of vitamin D toxicity. Bone Miner. 1990 Dec;11(3):267–272. doi: 10.1016/0169-6009(90)90023-9. [DOI] [PubMed] [Google Scholar]
  35. Zhou J. Y., Norman A. W., Chen D. L., Sun G. W., Uskokovic M., Koeffler H. P. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A. 1990 May;87(10):3929–3932. doi: 10.1073/pnas.87.10.3929. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES